Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies
Over 30 years of experience in the pharmaceutical world. Also engaged in medical technologies, e.g. maintaining a distribution network for high-end ICU products in Central Europe. He recognizes the potential of combining highly specialized experts with the current trends, e.g. such as drug delivery for medicinal Cannabis.
Mireca Medicines GmbH
Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis (LCA) and Stargardt’s Disease (STGD) are rare eye diseases leading to severe vision impairment or blindness. Within the eye, they cause degeneration of the photoreceptors responsible for conversion of light into signals to be sent to the brain. The conditions are inherited and caused by ~250 different gene mutations. They affect a combined 450,000 people within the EU, Japan and the US. To date, no treatment is available for RP, LCA and STGD. Mireca wants to develop drug candidate LP–DF 003 which uses a novel approach for the treatment of the conditions. In contrast to current gene therapies, which address specific gene mutations, Mireca’s approach is significantly broader and assumed suitable to target at least one third of the various gene mutations. Based on the promising outcomes of the EU (FP7) funded DRUGSFORD project, Mireca benefits from completed pre-clinical pharmacology and initial safety testing, an existing orphan drug designation granted by the EMA, a GMP-compliant production process, 3 patent applications and exclusive licensing agreements. Beyond currently planned product developments, Mireca has access to a platform technology for the potential treatment of several neurodegenerative diseases. Mireca has been set up as a German limited liability company (“GmbH”) located in Tuebingen (~40 kilometers south of DE-Stuttgart). Mireca’s experienced international management team combines broad and deep scientific as well as business experience. Mireca wants to transition LP-DF003 into clinical studies and aims to obtain market authorizations for RP, LCA and STGD treatment products starting in the year 2024.